Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Urothelial Carcinoma
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Nivolumab
Sponsor: Daiichi Sankyo
Collaborators: Bristol-Myers Squibb|AstraZeneca